What's in Pronova BioPharma's pipeline?

Pronova BioPharma has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Pronova BioPharma's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/pronova-biopharma.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Pronova BioPharma — Portfolio Competitive Intelligence Brief

Pronova BioPharma pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Omega-3-acid ethyl esters 90	Omega-3-acid ethyl esters 90	marketed	Fibrate-like lipid-lowering agent / Omega-3 fatty acid		Cardiovascular
Statins	Statins	marketed			Other

Therapeutic area mix

Cardiovascular · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Pronova BioPharma:

Cite this brief

Drug Landscape (2026). Pronova BioPharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pronova-biopharma. Accessed 2026-05-16.